Procedural Pharmaceutical Lessons From Early Adopters - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Procedural Pharmaceutical Lessons From Early Adopters

  • September 1, 2026

  • 18 min

Share

Objective:

To share insights from experienced glaucoma surgeons on integrating sustained drug delivery into glaucoma management.

Approach:
  • Patient Selection and Counseling: Surgeons discuss the importance of individualized treatment plans and effective communication with patients regarding sustained drug delivery options.
Key Findings:
  • Sustained-release pharmaceuticals like Durysta and iDose TR provide alternatives to daily topical therapy.
  • Patient education and counseling are essential for the acceptance of procedural pharmaceuticals.
  • Surgeons highlight the importance of individualized treatment options over traditional drop therapy.
Interpretation:

The integration of sustained drug delivery into glaucoma treatment requires a shift in approach among surgeons and patients.

Limitations:
  • The article does not provide quantitative data on the effectiveness of sustained drug delivery compared to traditional therapies.
  • Insights are based on individual experiences and may not be applicable to all practices.
Conclusion:

Surgeons are adapting their approaches to include sustained drug delivery as a potential option in glaucoma management.

Original Source(s)

Related Content